Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REDWOOD CITY, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON CORPORATE PROGRESS.

REVOLUTION MEDICINES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS

REDWOOD CITY, CALIF., JULY 30, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 ON WEDNESDAY, AUGUST 6, 2025, AFTER MARKET CLOSE. AT 4:30 P.M. ET THAT DAY (1:30 P.M. PT), MEMBERS OF REVOLUTION MEDICINES' SENIOR MANAGEMENT TEAM WILL HOST A WEBCAST TO DISCUSS THE FINANCIAL RESULTS FOR THE QUARTER AND PROVIDE AN UPDATE ON CORPORATE PROGRESS.

REVOLUTION MEDICINES TO REPORT FINANCIAL RESULTS FOR SECOND QUARTER 2025 AFTER MARKET CLOSE ON AUGUST 6, 2025

REDWOOD CITY, CALIF., JULY 24, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THE PUBLICATION OF A PEER-REVIEWED RESEARCH PAPER IN SCIENCE. THE SCIENTIFIC PAPER DETAILS THE DISCOVERY AND DEVELOPMENT OF ZOLDONRASIB (RMC-9805), A RAS(ON) G12D-SELECTIVE COVALENT INHIBITOR.

REVOLUTION MEDICINES ANNOUNCES PUBLICATION OF A PEER-REVIEWED RESEARCH PAPER IN SCIENCE ON THE DISCOVERY AND DEVELOPMENT OF ZOLDONRASIB, A RAS(ON) G12D-SELECTIVE INHIBITOR

BREAKTHROUGH THERAPY DESIGNATION GRANTED TO ELIRONRASIB FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY AND IMMUNOTHERAPY BUT HAVE NOT BEEN PREVIOUSLY TREATED WITH A KRAS G12C INHIBITOR DESIGNATION BASED ON ENCOURAGING CLINICAL DATA OBSERVED WITH ELIRONRASIB IN PATIENTS WITH ADVANCED KRAS G12C NON-SMALL CELL LUNG CANCER REDWOOD CITY, CALIF., JULY 23, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO ELIRONRASIB, THE COMPANY'S RAS(ON) G12C-SELECTIVE INHIBITOR, FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY AND IMMUNOTHERAPY BUT HAVE NOT BEEN PREVIOUSLY TREATED WITH A KRAS G12C INHIBITOR.

REVOLUTION MEDICINES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR ELIRONRASIB

CUSTOM-BUILT MODEL WILL BE TRAINED USING REVOLUTION MEDICINES' PROPRIETARY DATA TO DISCOVER NOVEL DRUG CANDIDATES IAMBIC TO RECEIVE UP TO $25 MILLION THROUGH A COMBINATION OF UPFRONT AND EXPECTED NEAR-TERM PERFORMANCE-BASED MILESTONE PAYMENTS FOR SERVICES RELATED TO REVOLUTION MEDICINES' ACCESS TO IAMBIC'S INDUSTRY-LEADING NEURALPLEXER MODEL FOR PROTEIN STRUCTURE PREDICTION REDWOOD CITY, CALIF. AND SAN DIEGO, JULY 09, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, AND IAMBIC THERAPEUTICS, A CLINICAL-STAGE LIFE SCIENCE AND TECHNOLOGY COMPANY DEVELOPING NOVEL MEDICINES USING ITS AI-DRIVEN DISCOVERY AND DEVELOPMENT PLATFORM, TODAY ANNOUNCED A TECHNOLOGY AND RESEARCH COLLABORATION TO PURSUE NOVEL DRUG CANDIDATES USING IAMBIC'S LEADING AI MODELS.

REVOLUTION MEDICINES AND IAMBIC ANNOUNCE TECHNOLOGY AND RESEARCH COLLABORATION USING IAMBIC'S AI DISCOVERY TOOLS TO PURSUE NEW DRUG CANDIDATES

REDWOOD CITY, CALIF. & MIAMI--(BUSINESS WIRE)---- $SMMT--REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS AND SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT), A BIOPHARMACEUTICAL ONCOLOGY COMPANY FOCUSED ON PATIENT-FRIENDLY MEDICINAL THERAPIES INTENDED TO IMPROVE QUALITY OF LIFE, INCREASE POTENTIAL DURATION OF LIFE, AND RESOLVE SERIOUS UNMET MEDICAL NEEDS, TODAY ANNOUNCED THE COMPANIES HAVE ENTERED INTO A CLINIC.

REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS(ON) INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORS

REDWOOD CITY, CALIF., JUNE 24, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT IT HAS PARTNERED WITH ROYALTY PHARMA ON $2 BILLION IN FLEXIBLE FUNDING TO SUPPORT REVOLUTION MEDICINES' INDEPENDENT GLOBAL DEVELOPMENT AND COMMERCIALIZATION STRATEGY AND OPERATIONS. REVOLUTION MEDICINES RETAINS FULL STRATEGIC AND EXECUTIONAL CONTROL OF PRODUCT DEVELOPMENT AND COMMERCIALIZATION FOR ITS PORTFOLIO OF RAS(ON) INHIBITORS IN THE US AND INTERNATIONALLY, ENABLING THE COMPANY TO LEVERAGE ITS ASSETS, CAPABILITIES AND MOMENTUM TOWARD ESTABLISHING NEW GLOBAL STANDARDS OF CARE AND CREATING VALUE FOR SHAREHOLDERS.

REVOLUTION MEDICINES ENTERS INTO $2 BILLION FLEXIBLE FUNDING AGREEMENT WITH ROYALTY PHARMA TO SUPPORT GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF RAS(ON) INHIBITOR PORTFOLIO FOR PATIENTS WITH RAS-ADDICTED CANCERS

REDWOOD CITY, CALIF., JUNE 23, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO DARAXONRASIB, THE COMPANY'S RAS(ON) MULTI-SELECTIVE INHIBITOR, FOR PREVIOUSLY TREATED METASTATIC PDAC IN PATIENTS WITH KRAS G12 MUTATIONS.

REVOLUTION MEDICINES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DARAXONRASIB IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER WITH KRAS G12 MUTATIONS

REDWOOD CITY, CALIF., MAY 14, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THE FIRST PATIENT HAS BEEN DOSED IN RASOLVE 301, A GLOBAL, RANDOMIZED, OPEN-LABEL PHASE 3 CLINICAL TRIAL.

REVOLUTION MEDICINES ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL EVALUATING DARAXONRASIB IN PREVIOUSLY TREATED PATIENTS WITH RAS MUTANT NON-SMALL CELL LUNG CANCER

REDWOOD CITY, CALIF., MAY 07, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2025, AND PROVIDED AN UPDATE ON CORPORATE PROGRESS.

Revolution Medicines, Inc.

RVMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Revolution Medicines, Inc.

RVMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RVMD